NT5E and acute myeloid leukemia: Blockade antibodies against CD73 are currently under active clinical studies for treating solid tumors (NCT03454451, NCT02503774); Furthermore, recent studies demonstrate the potential of CD73 in antileukemic immunity in AML [28].